ArticleBMJ open2025

Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation.

Dan Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.